These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 23462853)

  • 1. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
    Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.
    Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2111-7. PubMed ID: 21497451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
    Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
    Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
    Niwińska A; Olszewski W; Murawska M; Pogoda K
    J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer subtypes and survival in patients with brain metastases.
    Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
    Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
    Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort.
    Jeon W; Jang BS; Jeon SH; Kim JH; Kim YJ; Kim SH; Kim CY; Han JH; Kim IA
    Breast J; 2018 Nov; 24(6):920-926. PubMed ID: 30596408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases.
    Fabregat-Franco C; Stradella A; Navarro V; Linares J; Galdeano M; Recalde S; Velasco R; Simo M; Fernadez A; Venthecourt AC; Falo C; Vazquez S; Bergamino M; Villanueva R; Pernas S; Gil-Gil MJ
    Clin Transl Oncol; 2021 Sep; 23(9):1761-1768. PubMed ID: 33704689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery.
    Vern-Gross TZ; Lawrence JA; Case LD; McMullen KP; Bourland JD; Metheny-Barlow LJ; Ellis TL; Tatter SB; Shaw EG; Urbanic JJ; Chan MD
    J Neurooncol; 2012 Dec; 110(3):381-8. PubMed ID: 23001361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.
    Griguolo G; Jacot W; Kantelhardt E; Dieci MV; Bourgier C; Thomssen C; Bailleux C; Miglietta F; Braccini AL; Conte P; Ferrero JM; Guarneri V; Darlix A
    Breast; 2018 Feb; 37():36-41. PubMed ID: 29073498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
    Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
    Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
    Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases.
    Michel A; Oppong MD; Rauschenbach L; Pierscianek D; Dinger TF; Schmidt T; Hense J; Pöttgen C; Kimmig R; Ahmadipour Y; Özkan N; Müller O; Junker A; Sure U; Jabbarli R; El Hindy N
    World Neurosurg; 2021 Aug; 152():e332-e343. PubMed ID: 34062302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.